Target delineation and optimal radiosurgical dose for pituitary tumors

Radiation Oncology

Table 3 Selected published results of SRS (2000–2015) for the treatment of ATCH-secreting pituitary adenomas

Authors	Patients	Type	dose	Follow-up	Tumor	Biochemical	Late toxicity (%)
Authors	Patients	of SRS	(Gy)	(months)	control (%)	remission (%)	visual	hypopituitarism
Izawa et al., 2000 [85]	12	GK	23.8^a	26.4	100	17	NA	0
Sheehan et al., 2000 [113]	43	GK	20^a	44	100	63	2	16
Hoybye et al., 2001 [114]	18	GK	>25^a	17 years	100	83	0	66
Devin et al., 2004 [115]	35	LINAC	14.7	35	91	49	0	40
Voges et al., 2006 [66]	17	LINAC	16.4	58.7	82.4	52.9	1.4	12.3
Castinetti et al., 2007 [116]	40	GK	29.5^a	54.7	100	42.5	2.5	15
Jagannathan et al., 2007 [117]	90	GK	25^a	45	96	54	5.5	22
Petit et al., 2007 [92]	33	Protons	20	62	94	52	0	52
Pollock et al., 2008 [118]	8	GK	18^a	54	100	87	0	36
Tinnel et al., 2008 [119]	12	GK	25^a	37	83.3	50	0	50
Wan et al., 2009 [98]	68	GK	23^a	67.3	89.7	27.9	2.9	1.7
Kobayashi et al., 2009 [120]	30	GK	28.7^a	64.1	100	35	NA	NA
Hayashi et al., 2010 [70]	13	GK	25.2^a	36	97	38	15.4	0
Sicignano et al., 2012 [37]	15	GK	23.8^a	60	97.7	64	NA	12.3
Wein et al., 2012 [120]	17	LINAC	18	23	94.1	58.8	0	11.8
Zeiler et al., 2013 [105]	8	GK	24.7^a	35	100	50	3.9	13.2
Grant et al., 2013 [121]	15	GK	35^a	40.2	100	73	3.2	32
Sheehan et al., 2013 [122]	96	GK	22^a	48	98	70	5	36
Wattson et al., 2014 [109]	74	Protons	20	47	98.6	67at 5 years	0	62 at 5 years
Wilson et al., 2014 [123]	36	LINAC	20	66	97	25	0	13.9
Marek et al., 2015 [35]	26	GK	29^a	78	91.9	80.7	0	11.5

SRS stereotactic radiosurgery, GK Gamma Knife, LINAC Linear Accelerator, CK CyberKnife, NA not assessed\
^amarginal dose

ISSN: 1748-717X